GANEDEN BIOTECH, INC. Names Frank X. Braun as Vice President for Military and Federal Programs;...

Business Editors, Health/Medical & Defense Writers

BIOWIRE2K

CLEVELAND--(BW HealthWire)--Aug. 6, 2001

Paul Locigno, the CEO of Ganeden Biotech announced the appointment of Frank X. Braun, retired Marine Corps Lieutenant Colonel as Vice President of its newly formed

Military and Federal Programs Group. Lt. Col (ret) Braun will head the working group responsible for Ganeden's Military and Federal Programs. Braun has a wide depth of 23 years experience in leadership and management positions involving market development, contract oversight, requirement analysis, and acquisition and procurement within military and federal agencies and in the private sector. Mr. Braun will be based in the Company's northern Virginia location.

Braun's military service includes: Director of International Programs, Marine Corps Systems Command; and Program Officer, Program Information Branch of Marine Corps Research, Development & Acquisition Command. Brauns' distinguished military service also included tours of duty as Commanding Officer of Headquarters Squadron, Marine Corps Air Station, Tustin, CA. and Chief Aircraft Maintenance Officer for the Squadron. His private sector experience encompasses market/sales development, federal contact award and oversight, and executive level consulting for requirement analysis and procurement.

Braun is a graduate of U.S. Defense Systems Management College, Ft. Belvoir, Va., and has a M.A. in Management from Webster University and a B.A. in Political Science from the University of Mississippi.

Ganeden Biotech Inc. is a Cleveland, Ohio-based health care company engaged in the discovery, development, and commercialization of therapeutic products based on the unique properties of lactic acid producing bacteria. Ganeden Biotech Inc. has developed new products that mitigate a multitude of human disease and, separately, have extraordinary applications as an animal feed supplement.

The Company is prepared to file IND's with the FDA for combined Phase I/II Studies on the Company's treatment of four diseases: (1) Nail Infections, (2) Vancomycin Resistant Enterococcus, (3) Irritable Bowel Syndrome, and (4) Vaginal Yeast Infections.

Web: www.clearlyconfident.com